New biological investigations on 3-bromophenyl 6-acetoxymethyl-2-oxo-2H-1- benzopyran-3-carboxylate as anti-angiogenic agent

Drug Development Research

Volumn 71, Issue 3, 2010, Pages 209-218

  Hemmer, Marc ^a,b   Kempen, Isabelle ^a   De Tullio, Pascal ^a   Frankenne, Francis ^a   Lambert, Vincent ^a   Blacher, Silvia ^a   Bueb, Jean Luc ^b   Foidart, Jean Michel ^a   Noël, Agnès ^a   Tschirhart, Eric ^b   Pirotte, Bernard ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LUXEMBOURG   (Luxembourg)

Author keywords

Age related macular degeneration; Angiogenesis; Anti angiogenic agents; Cancer; Coumarin derivatives

Indexed keywords

3 BROMOPHENYL 6 ACETOXYMETHYL 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; ANGIOGENESIS INHIBITOR; BENZOPYRAN DERIVATIVE; CAMPTOTHECIN; IK 9; MATRIX METALLOPROTEINASE INHIBITOR; RO 282653; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; ENDOTHELIUM CELL; EX VIVO STUDY; FIBROSARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; SUBRETINAL NEOVASCULARIZATION; VASCULAR RING;

EID: 77952786376     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20364     Document Type: Article

References (38)

1. Alfano RW, Leppla SH, Liu S, Bugge TH, Duesbery NS, Frankel AE. 2008. Potent inhibition of tumor angiogenesis by the matrix metalloproteinase- activated anthrax lethal toxin: implications for broad anti-tumor efficacy. Cell Cycle 7:745-749.
2. Andrae J, Gallini R, Betsholtz C. 2008. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276-1312.
3. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. 1999. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228.
4. Berndt S, Bruyère F, Jost M, Noël A. 2008. In vitro and in vivo models of angiogenesis to dissect MMP functions. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF, editors. The cancer degradome-proteases and cancer biology. New York: Springer. p 305-325.
5. Blacher S, Devy L, Burbridge MF, Roland G, Tucker G, Noël A, Foidart JM. 2001. Improved quantification of angiogenesis in the rat aortic ring assay. Angiogenesis 4:133-142. (Pubitemid 34032699)
6. Bruyère F, Noël A. 2009. Lymphangiogenesis: in vitro and in vivo models. FASEB J 24:8-21.
7. Carmeliet P. 2005. Angiogenesis in life, disease and medicine. Nature 438:932-936.
8. Daniewski AR, Liu W, Okabe M. 2004. An improved synthesis of the selective matrix metalloproteinase inhibitor, Ro 28-2653. Org Proc Res Dev 8:411-414. (Pubitemid 38829038)
9. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, et al. 2002. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16:147-154. (Pubitemid 34113008)
10. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186.
11. Folkman J, Shing Y. 1992. Angiogenesis. J Biol Chem 267:10931-10934.
12. Gerhardt H, Betsholtz C. 2003. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314:15-23.
13. Gupta GP, Massague J. 2006. Cancer metastasis: building a framework. Cell 127:679-695.
14. Han S, Zhou V, Pan S, Liu Y, Hornsby M, McMullan D, Klock HE, Haugen J, Lesley SA, Gray N, et al. 2005. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg Med Chem Lett 15:5467-5473. (Pubitemid 41562972)
15. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364. (Pubitemid 26272076)
16. Joseph IB, Vukanovic J, Isaacs JT. 1996. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res 56:3404-3408. (Pubitemid 26251627)
17. Jost M, Maillard C, Lecomte J, Lambert V, Tjwa M, Blaise P, Alvarez Gonzalez ML, Bajou K, Blacher S, Motte P, et al. 2007. Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I. Am J Pathol 171:1369-1380. (Pubitemid 47582909)
18. Kalluri R. 2003. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3:422-433. (Pubitemid 37328846)
19. Kempen I, Hemmer M, Counerotte S, Pochet L, de Tullio P, Foidart JM, Blacher S, Noël A, Frankenne F, Pirotte B. 2008. 6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid derivatives in a new approach of the treatment of cancer cell invasion and metastasis. Eur J Med Chem 43:2735-2750.
20. Kempen I, Papapostolou D, Thierry N, Pochet L, Counerotte S, Masereel B, Foidart JM, Reboud-Ravaux M, Noël A, Pirotte B. 2003. 3-Bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate inhibits cancer cell invasion in vitro and tumour growth in vivo. Br J Cancer 88:1111-1118. (Pubitemid 36560785)
21. Lambert V, Munaut C, Noël A, Frankenne F, Bajou K, Gerard R, Carmeliet P, Defresne MP, Foidart JM, Rakic JM. 2001. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 15:1021-1027. (Pubitemid 32290790)
22. Maquoi E, Sounni NE, Devy L, Olivier F, Frankenne F, Krell HW, Grams F, Foidart JM, Noël A. 2004. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 10:4038-4047. (Pubitemid 38812479)
23. Mazzocca A, Carloni V. 2009. The metastatic process: methodological advances and pharmacological challenges. Curr Med Chem 16:1704-1717.
24. Nicosia RF, Ottinetti A. 1990a. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 63:115-122.
25. Nicosia RF, Ottinetti A. 1990b. Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol 26:119-128.
26. Noël A, Jost M, Lambert V, Lecomte J, Rakic JM. 2007. Antiangiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts. Trends Mol Med 13:345-352.
27. Ostman A. 2004. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15:275-286.
28. Pan R, Dai Y, Yang J, Li Y, Yao X, Xia Y. 2009. Anti-angiogenic potential of scopoletin is associated with the inhibition of ERK1/2 activation. Drug Dev Res 70:214-219.
29. Pochet L, Doucet C, Schynts M, Thierry N, Boggetto N, Pirotte B, Jiang KY, Masereel B, de Tullio P, Delarge J, et al. 1996. Esters and amides of 6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-carboxylic acid as inhibitors of alpha-chymotrypsin: significance of the "aromatic" nature of the novel ester-type coumarin for strong inhibitory activity. J Med Chem 39:2579-2585.
30. Pochet L, Doucet C, Dive G, Wouters J, Masereel B, Reboud-Ravaux M, Pirotte B. 2000. Coumarinic derivatives as mechanism-based inhibitors of alpha-chymotrypsin and human leukocyte elastase. Bioorg Med Chem 8:1489-1501.
31. Rundhaug JE. 2005. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9:267-285.
32. Sengupta N, Caballero S, Mames RN, Butler JM, Scott EW, Grant MB. 2003. The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest Ophthalmol Vis Sci 44:4908-4913. (Pubitemid 37315308)
33. Shi J, Xiao Z, Ihnat MA, Kamat C, Pandit B, Hu Z, Li PK. 2003. Structure-activity relationships studies of the anti-angiogenic activities of linomide. Bioorg Med Chem Lett 13:1187-1189.
34. Shibuya M. 2001. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26:25-35. (Pubitemid 32421949)
35. Tomita M, Yamada H, Adachi Y, Cui Y, Yamada E, Higuchi A, Minamino K, Suzuki Y, Matsumura M, Ikehara S. 2004. Choroidal neovascularization is provided by bone marrow cells. Stem Cells 22:21-26. (Pubitemid 38018778)
36. Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley-Asp B, Isaacs JT. 1993. Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 53:1833-1837.
37. Zetter BR. 1998. Angiogenesis and tumor metastasis. Annu Rev Med 49:407-424.
38. Zhong H, Bowen JP. 2006. Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Curr Med Chem 13:849-862.